Skip to main content

Table 1 Different published studies exploring the impact of the global lymphopenia or NK and T cell subsets on relapse-free survival (RFS) or overall survival (OS) in patients with solid tumors

From: Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?

Tumor Type N Type of lymphopenia evlauated Lymphocyte Threshold (% lymphopenia) RFS (Cox Analysis) OS (Cox Analysis) References
RR IC 95% P value RR IC 95% P value
Sarcoma 193 Overall Lymphopenia <1000 (24%) Not evaluated 1.46 1.0-2.1 0.05 [68]
Ewing Sarcoma 24 Overall Lymphopenia <500 (33%) Not evaluated 4.34 1.35-14.28 0.007 [75]
Renal Cell Carcinoma 424 Overall Lymphopenia ≤1300 (28.06%) Not evaluated 1.75 1.14-2.67 0.0102 [65]
Colon Carcinoma 260 Overall Lymphopenia <1000 (19%) 1.56 1.0-2.43 0.048 2.35 2.34-4.14 0.003 [66]
Breast Carcinoma 195 Overall Lymphopenia <1000 (28.7%) 1.82 1.27-2.59 0.001 2.23 1.36-3.65 0.001 [89]
Non Hodgkin Lymphoma 322 Overall Lymphopenia <1000 (25%) 1.71 1.2-2.4 0.002 1.48 1.03-2.21 0.04 [68]
Diffuse large B cell lymphoma (DLBCL) 151 Overall Lymphopenia ≤1000 (35.8%) Not evaluated 2.38 1.29-4.34 0.005 [90]
DLBCL 221 Overall Lymphopenia <1000 (38.9%) 2.72 1.61-4.60 <0.001 2.51 1.38-4.58 0.003 [80]
DLBCL 89 Overall Lymphopenia <840 (23%) 3.81 1.72-8.42 0.0009 4.38 1.88-13.28 0.0012 [79]
Follicular Lymphoma 228 Overall Lymphopenia ≤1000 (28%) Not evaluated 1.72 1.33-2.24 <10-4 [70]
Hodgkin Lymphoma 476 Overall Lymphopenia <600 (18.06%) 1.59 0.96-2.58 0.06 1.25 0.74-2.15 0.4 [82]
Hodgkin Lymphoma 2497 Overall Lymphopenia <600 (11%) 1.38   0.002 Not evaluated [81]
Multiple Myeloma 537 Overall Lymphopenia <1400 (62%) Not evaluated 1.71 1.53-2.35 <10-4 [92]
ATLL 60 Overall Lymphopenia <1000 (35.6%) 1.93   0.004 2.37   0.0003 [93]
PTCLU 69 Overall Lymphopenia <1000 (38%) Not evaluated 4.0 1.9-8.3 <10-4 [71]
PTCL-NOS 118 Overall Lymphopenia 1000 (30.5%) 1.94 1.19-3.18 0.008 2.24 1.33-3.78 0.002 [72]
Breast Carcinoma 287 Overall Lymphopenia <1000 (27%) 1.48 1.1-2.0 0.01 1.8 1.3-2.4 0.0002 [68]
Breast Carcinoma 195 Overall Lymphopenia <1000 (28.7%) 1.82 1.27-2.59 0.001 2.23 1.36-3.65 0.001 [89]
Breast Carcinoma 1st relapse 128 Overall Lymphopenia <1000 (44.27%) Not evaluated 1.8 1.15-2.82 0.01 [50]b
Breast Carcinoma 1st relapse
1st relapse
103 Overall Lymphopenia <700 (22.3%) Not evaluated 2.03 1.17-3.50 0.016 [21]b
Breast Carcinoma 1st relapse
1st relapse
103 CD4+ Lymphopenia ≤450 (53.4%) Not evaluated 2.50 1.57-3.98 <10-4 [21]b
Breast Carcinoma >2nd relapse 101 CD4+ Lymphopenia ≤450 (70.3%) 1.35 0.87-1.1 0.183 1.69 1.04-2.78 0.036 [21]
Metastatic Solid Tumors 219 CD4+ Lymphopenia ≤450 (47.9%) Not evaluated 1.5 1.1-2.1 0.017 [20]
Metastatic Solid Tumors 213 CD4+ Lymphopenia <450 (49.7%) Not evaluated 7.7a 1.6-35a 0.007a [19]a
Non Hodgkin Lymphoma 88 CD8+ Lymphopenia <200 Not evaluated 3.30 1.21-9.0 0.01 [88]
Follicular Lymphoma 75 NK cells Lymphopenia <150 (44%) Not evaluated 6.73 0.76-59 0.08 [69]
DLBCL 136 NK cells Lymphopenia ≤80 (37.5%) 1.81 1.27-2.57 0.001 Not evaluated [94]
  1. a Analysis of the risk of early death; b Univariate analysis only